ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Co-stimulation"

  • 2021 American Transplant Congress

    Association of Belatacept Conversion on Patient and Allograft Survival in Kidney Transplant Recipients with Congestive Heart Failure

    H. Mogallapalli

    Department of Medicine, University of Wisconsin-Madison, Madison, WI

    *Purpose: Calcineurin inhibitors (CNI) exert deleterious effect on cardiovascular risk in kidney transplant recipients (KTRs). Belatacept conversion may reduce CV risk in KTRs. We hypothesized…
  • 2021 American Transplant Congress

    Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?

    M. McGowan1, A. Bickenbach1, B. Miyagawa2, A. Christianson1, T. Mizuno2, P. West-Thielke3, J. Leone4, E. Woodle1, D. Kaufman5, A. Wiseman6, A. Matas7, A. Vinks2, R. Alloway1

    1U Cincinnati, Cincinnati, OH, 2Cincinnati Children's Med Center, Cincinnati, OH, 3U Illinois, Chicago, IL, 4Tampa Gen, Tampa, FL, 5U Wisconsin, Madison, OH, 6Centura Transplant, Denver, CO, 7U Minnesota, Minneapolis, MN

    *Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…
  • 2021 American Transplant Congress

    Obesity Impacts Acute Rejection but Not Allograft Function Improvement in the Setting of Belatacept Conversion

    D. Pierce, J. Benken, P. West-Thielke, I. Tzvetanov, E. Benedetti, A. Lichvar

    University of Illinois at Chicago, Chicago, IL

    *Purpose: There is limited data regarding belatacept conversion in obese patients as an alternative to calcineurin inhibitor (CNI) immunosuppression. Pharmacokinetic (PK) data suggests increasing clearance…
  • 2021 American Transplant Congress

    P40 Homodimers Induce Il-15 to Promote Endogenous Donor-reactive Memory Cd8 T Cell Activation within High-risk Cardiac Allografts

    H. Tsuda, A. Valujskikh, R. Fairchild

    Inflammation and Immunity, Cleveland Clinic, Cleveland, OH

    *Purpose: Longer cold ischemic storage (CIS) time prior to transplant results in increased proliferation of endogenous donor-reactive memory CD8 T cells within complete MHC-mismatched cardiac…
  • 2021 American Transplant Congress

    Kidney Transplant Outcomes Stratified by Race with a Calcineurin and Steroid Free Regimen

    R. E. Scalzo, M. T. Harris, J. D. Morris, J. S. Byrns

    Pharmacy, Duke University Medical Center, Durham, NC

    *Purpose: This study aimed to describe the outcomes, stratified by race, associated with belatacept and sirolimus immunosuppression after alemtuzumab induction.*Methods: This was a retrospective, single-center…
  • 2021 American Transplant Congress

    Immunosuppression Reduction Strategies for Polyoma BK Viremia in Kidney Transplant Patients on Belatacept-Based Immunosuppression

    O. Roe1, E. Meredith1, A. Reid2, A. Basu3

    1Emory University Hospital, Atlanta, GA, 2University of California San Francisco Medical Center, San Francisco, CA, 3Emory Transplant Center, Atlanta, GA

    *Purpose: The mainstay of treatment for BK infection is immunosuppression (IS) reduction, however limited literature provides guidance for treatment of patients with a belatacept-based IS…
  • 2021 American Transplant Congress

    Kidney Transplant Outcomes Stratified by Age with a Calcineurin and Steroid Free Regimen

    R. Scalzo1, M. Harris1, J. Morris2, J. Byrns1

    1Pharmacy, Duke University Hospital, Durham, NC, 2Nephrology, Duke University Hospital, Durham, NC

    *Purpose: To evaluate the impact of an alemtuzumab, belatacept, and sirolimus based regimen on renal function stratified by age in kidney transplant (KT) patients.*Methods: This…
  • 2021 American Transplant Congress

    Life-supporting Multi-gene Cardiac Xenografts From Swine Demonstrate Survival >8 Months and Preclinical Efficacy for Human Clinical Trials

    C. Goerlich1, B. Griffith1, A. Singh1, T. Zhang1, I. Tatarov1, B. Lewis1, F. Sentz1, A. Hershfeld1, P. Odonkor1, B. Williams1, E. Strauss1, A. Tabatabai2, A. Bhutta3, D. Ayares4, D. Kaczorowski1, M. Mohiuddin1

    1Surgery, University of Maryland School of Medicine, Baltimore, MD, 2Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, 3Pediatrics, Pediatric Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, 4Revivicor, Inc., Blacksburg, VA

    *Purpose: Cardiac xenotransplantation has been proposed to bridge the gap in organ shortage for those in end-stage heart failure without the opportunity to receive a…
  • 2021 American Transplant Congress

    AT-1501, a Novel and Clinically Applicable CD40L Specific Monoclonal Antibody, Promotes Islet Allograft Survival in Nonhuman Primates

    D. Berman1, N. Kenyon1, M. Willman1, A. Gill2, S. Perrin3, C. Ricordi1

    1University of Miami, Miami, FL, 2ALS Therapy Development Institute, Cambridge, MA, 3Novus Therapeutics, Irvine, CA

    *Purpose: Immune intervention with a CD40L specific monoclonal antibody (mAb, Hu5c8, Biogen) has previously been shown to safely and effectively prevent islet allograft (IA) rejection…
  • 2021 American Transplant Congress

    Interruption of Notch Signaling via Blockade of Delta-Like Ligand 4 Prevents Co-Stimulation Blockade Resistant Allograft Rejection

    A. J. Matar, B. P. Lovasik, Y. Dong, D. A. Faber, J. Habib, C. Breeden, J. Regenold, A. Ghosh, A. Stephenson, W. H. Kitchens, A. B. Adams

    Emory University Department of Surgery, Atlanta, GA

    *Purpose: Co-stimulation blockade (CoB) has emerged as a promising immunosuppression strategy with the advent of Belatacept, a novel CTLA4-Ig fusion protein that blocks CD28-mediated T…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 30
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2026 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences